Praxis Precision Medicines (PRAX) GC reports new equity awards filing

Rhea-AI Filing Summary

Praxis Precision Medicines’ General Counsel and Secretary, Alex Nemiroff, reported new equity awards and a tax-related share withholding. On January 8, 2026, he was granted 6,875 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of the January 8, 2026 vesting start date.

On the same date, he also received a stock option for 5,500 shares at an exercise price of $294.38 per share, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service. On January 10, 2026, 917 common shares were withheld at $288.45 per share to cover tax obligations from previously reported RSU vesting, leaving 26,700.667 common shares held directly and 5,500 options outstanding.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nemiroff Alex

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		A(1)		6,875	A	$0	27,617.667	D
Common Stock	01/10/2026		F(2)		917	D	$288.45	26,700.667	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$294.38	01/08/2026		A		5,500		(3)	01/08/2036	Common Stock	5,500	$0	5,500	D

Explanation of Responses:

1. Mr. Nemiroff was awarded 6,875 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the one-year anniversary of the vesting commencement date of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

2. Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units.

3. The shares underlying this stock option vest over a four-year period, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.

Remarks:

	/s/ Alex Nemiroff	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did PRAX General Counsel Alex Nemiroff report on this Form 4?

Alex Nemiroff reported three items: a grant of 6,875 restricted stock units on January 8, 2026, a grant of a stock option for 5,500 shares at an exercise price of $294.38 on the same date, and the withholding of 917 common shares on January 10, 2026 to satisfy tax obligations from prior RSU vesting.

How do the new PRAX restricted stock units granted to Alex Nemiroff vest?

The 6,875 restricted stock units granted to Alex Nemiroff vest in equal annual installments over four years, beginning on the one-year anniversary of the vesting commencement date of January 8, 2026. Each vested unit settles in one share of Praxis common stock.

What are the terms of Alex Nemiroff’s new PRAX stock option award?

The stock option covers 5,500 shares of Praxis common stock at an exercise price of $294.38 per share. The shares underlying the option vest over four years, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to his continued service.

Why were 917 shares of PRAX common stock withheld from Alex Nemiroff?

The 917 common shares were withheld by Praxis on January 10, 2026 to satisfy tax withholding obligations arising from the vesting of previously reported restricted stock units, as described in the filing’s footnotes.

How many PRAX shares and options does Alex Nemiroff hold after these transactions?

Following the reported transactions, Alex Nemiroff directly owns 26,700.667 shares of Praxis common stock and holds 5,500 stock options to purchase additional shares, as stated in the filing.

What is Alex Nemiroff’s role at Praxis Precision Medicines (PRAX)?

Alex Nemiroff is an officer of Praxis Precision Medicines, serving as the company’s General Counsel and Secretary, according to the Form 4 disclosure.